20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Vera Therapeutics Inc (VERA) operates in the BIOTECHNOLOGY industry and is headquartered in Brisbane, United States with about 361 employees. Its market capitalization is roughly $2 billion. In the fiscal year ended 2025-12-31, VERA reported $0M in revenue and ($300M) in net income.
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases.
Interactive charts & full statements →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | — | $0M | $0M | $2M | $0M | $0M | $0M | $0M |
| Gross Profit | — | $0M | ($2M) | $2M | $1M | $0M | $0M | ($1M) |
| Gross Margin % | — | — | — | 100.0% | — | — | — | — |
| Operating Income (EBIT) | ($416M) | ($315M) | ($167M) | ($102M) | ($91M) | ($34M) | ($48M) | ($12M) |
| Operating Margin % | — | — | — | -5478.6% | — | — | — | — |
| Net Income | ($402M) | ($300M) | ($152M) | ($96M) | ($89M) | ($33M) | ($53M) | ($12M) |
| Net Margin % | — | — | — | -5155.2% | — | — | — | — |
| EBITDA | ($390M) | ($292M) | ($144M) | ($92M) | ($92M) | ($34M) | ($53M) | ($11M) |
| Earnings Per Share (EPS) | $-5.89 | $-4.66 | $-2.75 | $-2.25 | $-3.35 | $-2.43 | $-14.40 | $-3.46 |
| Shares Outstanding (M) | 72M | 64M | 55M | 43M | 27M | 13M | 4M | 3M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | — | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Gross Profit | — | $0M | $1M | ($1M) | ($1M) | — | — | — |
| Gross Margin % | — | — | — | — | — | — | — | — |
| Operating Income (EBIT) | ($112M) | ($125M) | ($94M) | ($84M) | ($80M) | ($57M) | ($49M) | ($50M) |
| Operating Margin % | — | — | — | — | — | — | — | — |
| Net Income | ($109M) | ($121M) | ($91M) | ($80M) | ($77M) | ($52M) | ($43M) | ($47M) |
| Net Margin % | — | — | — | — | — | — | — | — |
| EBITDA | ($107M) | ($119M) | ($85M) | ($78M) | ($74M) | ($50M) | ($41M) | ($45M) |
| Earnings Per Share (EPS) | $-1.52 | $-1.69 | $-1.42 | $-1.26 | $-1.20 | $-0.81 | $-0.79 | $-0.85 |
| Shares Outstanding (M) | 72M | 71M | 64M | 64M | 64M | 64M | 55M | 55M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($339M) | ($241M) | ($135M) | ($92M) | ($68M) | ($24M) | ($35M) | ($10M) |
| Capital Expenditures (CapEx) | $1M | $1M | $1M | $0M | $0M | $0M | $0M | $0M |
| Free Cash Flow (FCF) | ($339M) | ($242M) | ($136M) | ($92M) | ($68M) | ($24M) | ($35M) | ($10M) |
| FCF Margin % | — | — | — | -4954.0% | — | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($100M) | ($106M) | ($70M) | ($62M) | ($55M) | ($54M) | ($39M) | ($37M) |
| Capital Expenditures (CapEx) | $0M | $0M | $0M | $0M | $0M | $0M | $1M | $0M |
| Free Cash Flow (FCF) | ($100M) | ($107M) | ($70M) | ($62M) | ($55M) | ($55M) | ($40M) | ($37M) |
| FCF Margin % | — | — | — | — | — | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $533M | $735M | $656M | $176M | $131M | $84M | $55M | $5M |
| Cash & Cash Equivalents | $49M | $355M | $93M | $46M | $43M | $80M | $54M | $3M |
| Total Liabilities | $125M | $130M | $79M | $74M | $55M | $14M | $144M | $42M |
| Total Debt (Short + Long-Term) | $0M | $75M | $52M | $52M | $27M | $5M | $0M | $0M |
| Total Shareholders' Equity | $408M | $605M | $577M | $102M | $77M | $70M | ($89M) | ($37M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive VERA viewer.
About TickerBase · Data methodology & sources · Privacy · Terms